Gilead Sciences: Buy This Bargain Before It's Gone

Ridofranz/iStock via Getty Images My previous article, “Gilead Sciences: Seriously Undervalued At Peak Pessimism,” caused quite a stir in the comments, particularly from those Seeking Alpha readers who remain pessimistic about Gilead Sciences, Inc.'s (NASDAQ:GILD) business prospects. However, that hasn't stopped the company's stock price from rising more than 23% in less than three months. In this article, I'll present an analysis of the sales of its HIV and oncology franchises, the successes and failur ...